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Reply to Reviewer Comments 
Reviewer #1: Thank you for the opportunity to re-review this paper after revisions. Again, Sylvester et al 
are to be congratulated for this remarkable contribution to European Urology. 
The authors have not indicated on their revised manuscript where the revised changes are, making it 
difficult to find them. Overall, I believe the authors have sufficiently addressed Reviewer #1's 
suggestions/comments.  
Reply: Thank you. Both the text of the revisions and the line numbers where changes were made to the 
manuscript were included in the reply to the reviewers. 
However for Reviewer #2, there are some inadequate responses from the authors.  
Reviewer 2 point 4 
- I believe that the authors should include a discussion on other types of meta-analyses, such as 
diagnostic test accuracy (e.g. PMID 27363387), prognostic factors (e.g. PMID 25559810), and even that 
of retrospective studies (e.g. PMID 24680361).  
- Again, despite what the authors feel about observational data, these represent real-world 
comparative effectiveness data that are typically of the patients we treat and therefore such data is 
practical, useful and believable to us as clinicians.  
- Additionally, for some rarer diseases such as UTUC, there just are not any RCTs and the best 
level of evidence will be a meta-analysis of all available retrospective studies.  
Reply: 
There are 6 important areas to consider when evaluating the validity and risk of bias in studies of 
prognostic factors (QUIPS): study participation, study attrition, prognostic factor measurement, study 
confounding, outcome measurement, and analysis and reporting. In order to minimize the risk of bias, 
prognostic factor studies to be included in a meta-analysis should preferably be prospective and have a 
protocol which addresses these topics. 
Reference: 
Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of 
prognostic factors. Ann Intern Med. 2013; 158:280-6. 
For diagnostic test accuracy studies, QUADAS-2 provides a tool for the quality assessment of diagnostic 
test accuracy studies which comprises 4 domains for assessing the risk of bias: patient selection, index 
test, reference standard, and flow and timing. Once again, in order to minimize the risk of bias, 
diagnostic test accuracy studies to be included in a meta-analysis should preferably be prospective and 
have a protocol which addresses these issues. 
Reference: 
Whiting PF, Rutjes AWS, West ME. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic 
Accuracy Studies. Ann Intern Med. 2011; 155:529-536. 
*Revision notes
For prognostic factor and diagnostic test accuracy systematic reviews, we agree with the reviewer that 
randomized controlled trials are not required, however the individual studies included in the meta-
analysis should preferably be prospective in nature and have a protocol in order to minimize the risk of 
bias. 
Since the manuscript deals primarily with discrepancies between intervention RCTs and meta-analyses, 
including meta-analyses involving diagnostic test accuracy and prognostic factor studies goes beyond 
the scope of the paper, notwithstanding the impact on the word count. Nevertheless, we have, as 
indicated below, added a sentence concerning them to the Discussion.   
We do not agree with the reviewer, however, that non-randomized comparative studies (whether 
prospective or retrospective) or observational case series should be included in meta-analyses of 
interventions because of the high risk of bias. Included in a qualitative systematic review, yes, but not 
included in a quantitative meta-analysis. The reasons for this position have already been outlined in our 
previous responses and are further discussed below. While we accept that some referees might have a 
different opinion, as a guideline authority we believe that this is an extremely important principle to 
uphold. 
For non RCT intervention effectiveness systematic reviews, one should present the results of the 
individual studies from a narrative point of view, in descriptive tables or even in forest plots, but the 
results of the individual studies should not be combined together in a formal meta-analysis to produce 
the diamond at the bottom of the forest plot. 
Although Stroup et al (MOOSE) provide a Reporting Checklist for Authors, Editors, and Reviewers of 
Meta-analyses of Observational Studies, they state in the Comment: 
“The application of formal meta-analytic methods to observational studies has been controversial. One 
reason for this has been that potential biases in the original studies, relative to the biases in RCTs, make 
the calculation of a single summary estimate of effect of exposure potentially misleading. Similarly, the 
extreme diversity of study designs and populations in epidemiology makes the interpretation of simple 
summaries problematic, at best. In addition, methodologic issues related specifically to meta-analysis, 
such as publication bias, could have particular impact when combining results of observational studies.” 
For example, the paper “Overall Survival Advantage with Partial Nephrectomy: A Bias of Observational 
Data?” by Shuch et al (reference 48), illustrates our concerns about bias when comparing partial 
nephrectomy to radical nephrectomy based on non RCT studies: 
“CONCLUSIONS: RN patients had similar OS compared with controls, suggesting that this treatment 
modality does not compromise survival. Patients undergoing PN had improved OS compared with 
controls, suggesting possible selection bias. The apparent survival advantage conferred by PN in SEER-
Medicare case series is likely the result of selection bias involving unmeasured confounders.” 
We thus feel that the risk of bias is too high in non RCT intervention effectiveness meta-analyses (where 
a formal risk of bias assessment of the individual studies isn’t always done) for their conclusions to 
directly impact on treatment recommendations and guidelines. Most readers will not be aware of their 
limitations.  We believe that it is better to present such results in a qualitative systematic review rather 
than to run the risk of publishing incorrect or misleading results in a meta-analysis that may steer 
further research in the wrong direction or adversely impact on patient care.  
- This is a paper submitted under Statistics in Urology, therefore the reply that "majority of whom 
do not have advanced statistical knowledge or experience" does not seem to be appropriate or 
accurate.  
Reply: It was submitted under Statistics in Urology for the lack of a better category. The most 
appropriate category would have been Guidelines, however this category does not exist. The paper is 
aimed at clinicians and guidelines developers and not at statisticians. In any case, the majority of 
readers, including those who read articles under the topic of Statistics in Urology, are urologists who do 
not have advanced statistical knowledge or experience.  
- This point should be addressed and included in the manuscript, rather than brushed aside, given 
the substantial proportion of systematic reviews and meta-analysis of not just RCTs, but other types of 
studies. 
Reply: As indicated in the paper’s title, the scope and subject of the paper is to resolve discordant 
findings between RCTs and meta-analyses. It was not our intent to deal with prognostic factor or 
diagnostic test accuracy meta-analyses, but only with intervention meta-analyses. Nevertheless, in 
accordance with the reviewer’s comments, the following modifications been made to the manuscript: 
Lines 321 – 323: 
It is important to reiterate that combining observational studies in general, and even comparative non-
randomized studies with RCTs in an intervention MA, may produce unreliable results and is not 
considered valid.   
In addition, the following text has been added in lines 330 – 333: 
Although non RCTs can be included in SRs, we have emphasized that only RCTs should be included in 
intervention MAs. RCTs are not required for prognostic factor and diagnostic test accuracy MAs, 
however the studies included in these MAs should preferably be prospective in nature and based on a 
protocol to minimize risk of bias. 
Reviewer #2:  
The authors have addressed most of my concerns. While I disagree with some of their responses, like 
those to questions #3, #4, and particularly #6, I think their responses are well thought out and certainly 
reasonable. I do feel, however, that these responses sure smell like those coming primarily from 
individuals that do not treat many patients.  
Reply: Seven of the 14 co-authors are urologists who regularly treat patients. 
The ITT vs PP analysis problem in my opinion clearly is best managed by presenting both results. How 
can one argue otherwise (i.e. for a less complete revelation of the data)?  
Reply: Unfortunately the risks associated with the results of a PP analysis are not often presented in the 
paper. Nevertheless, lines 93 - 96 have been modified as follows: 
In some RCTs, not all participants receive their randomized intervention; they may, for example, cross-
over to the other randomized treatment, in which case a per-protocol analysis may also provide useful 
information. 
Similarly, the hierarchy of evidence is actually not based in evidence! I wonder what would happen if we 
randomized patients to be treated by statistical robots or by experienced physicians? I bet the robots 
miss the boat because of the innumerable immeasurables that physicians, and not data-analysts, 
recognize and utilize. There is a reason some MDs get better results than others, and it is not better 
access to trial data. 
Reply: Yes, quality of results by MD or by institution is an important topic, and variations in outcomes 
may be linked to pre-existing experience, education, training, one’s innate ability to learn and adapt, 
institutional support and other elements of the learning curve. See, for example, the conclusions of the 
following paper: 
https://www.ncbi.nlm.nih.gov/pubmed/12074794 
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New or existing RCT data can lead to conflicts with MA data. In this paper, we present examples 
of, and explore reasons for, such conflicts. Guidance is provided to guideline developers on how 
to assess conflicting data in such circumstances to help determine which source is more 
reliable. For guideline organizations, both within and outside of urology, having a well-defined 
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guidelines. 
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Abstract 1 
Context: Clinicians and treatment guideline developers are faced with a dilemma when the 2 
results of a new, large, well conducted, randomized controlled trial (RCT) are in direct conflict 3 
with the results of a previous systematic review (SR) and meta-analysis (MA). 4 
Objective: To explore and discuss the possible reasons for disagreement in the results from 5 
SRs/MAs and RCTs and to provide guidance to clinicians and guideline developers for making 6 
well informed treatment decisions and recommendations in the face of conflicting data. 7 
Evidence Acquisition: The advantages and limitations of RCTs and SRs/MAs are reviewed. Two 8 
practical examples which have a direct bearing on EAU guidelines treatment recommendations 9 
are discussed in detail to illustrate the points to be considered when conflicts exist between the 10 
results of large RCTs and SRs/MAs. 11 
Evidence Synthesis: RCTs are the gold standard for providing evidence of the effectiveness of 12 
interventions, however concerns over an RCT’s internal and external validity may limit their 13 
applicability on clinical practice. SRs/MAs synthesize all evidence related to a given research 14 
question but two urological examples show that the validity of their results depends on the 15 
quality of the individual studies, the clinical and methodological heterogeneity of the studies, 16 
and publication bias. 17 
Conclusions: Although SRs/MAs can provide a higher level of evidence than RCTs, the quality of 18 
the evidence from both the RCT and the SR/MA should be investigated when their results 19 
conflict to determine which source provides the better evidence. Guideline developers should 20 
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have a well-defined and robust process to assess the evidence from MAs and RCTs when such 21 
conflicts exist. 22 
Patient Summary:  We discuss the advantages and limitations of using data from randomized 23 
controlled trials and systematic reviews/meta-analyses in informing clinical practice when there 24 
are conflicting results and provide guidance on how such conflicts should be dealt with by 25 
guideline organizations. 26 
Take Home Message 27 
New or existing RCT data can lead to conflicts with MA data. In this paper, we present examples 28 
of, and explore reasons for, such conflicts. Guidance is provided to guideline developers on how 29 
to assess conflicting data in such circumstances to help determine which source is more 30 
reliable. For guideline organizations, both within and outside of urology, having a well-defined 31 
and robust process to deal with such conflicts is essential to improve the quality of their 32 
guidelines. 33 
Tweets 34 
Clinicians: SRs/MAs theoretically provide a higher LE than RCTs, but their quality needs scrutiny 35 
in case of conflict #eauguidelines 36 
Patient summary: High level scientific publications should be interpreted with caution when 37 
there are conflicting results #eauguidelines 38 
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1. Introduction 39 
The practice of evidence based medicine means integrating individual clinical expertise with the 40 
best available external clinical evidence from systematic research [1]. 41 
Treatment recommendations in European Association of Urology (EAU) Guidelines are under-42 
pinned, whenever possible, by the results of systematic reviews (SR)/meta-analyses (MA) and 43 
large randomized controlled trials (RCT). According to the 2009 Oxford Centre for Evidence 44 
Based Medicine, SRs of RCTs (with or without a meta-analysis) that are free of worrisome 45 
variations (heterogeneity) in results between individual studies provide the highest level of 46 
evidence (LE), 1a, whereas individual RCTs with a narrow confidence interval provide the next 47 
highest LE, 1b [2]. As SRs can provide a higher LE than RCTs, the results of SRs are generally 48 
considered to take precedence when developing treatment recommendations.  49 
The quality of the results of a SR/MA depends on the quality of the included studies. Kjaergard 50 
et al [3] found a correlation between methodologic quality and discrepancies in the results of 51 
large and small RCTs included in MAs. Intervention effects were exaggerated in small trials with 52 
inadequate allocation sequence generation, inadequate allocation concealment and no double 53 
blinding.  54 
Discrepancies have also been noted between large RCTs and previously published MAs on the 55 
same subject [4-6]. In 12 large RCTs carried out subsequent to 19 MAs addressing the same 56 
question, LeLorier et al [7] found that the results of subsequent RCTs results disagreed with 57 
those of earlier MAs 35% of the time. 58 
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To illustrate these points and provide guidance to guideline developers in dealing with 59 
conflicting data from different sources, two examples which have a direct bearing on EAU 60 
Guidelines treatment recommendations are presented. In the first example, the EAU Guidelines 61 
Office has recently been confronted with the results of a large RCT which found no beneficial 62 
effect of medical expulsive therapy (MET) on stone passage, contrary to results of previous 63 
meta-analyses which formed the basis for treatment recommendations [8]. In the second 64 
example, which compares the efficacy of partial versus radical nephrectomy for localized renal 65 
tumors, discordance between the results of the meta-analysis and the only available RCT are 66 
investigated [9,10]. 67 
2. Advantages and Limitations of Randomized Controlled Trials 68 
As summarized in Table 1, RCTs have a number of advantages and limitations. 69 
Advantages of RCTs 70 
RCTs are the gold standard for providing evidence on the effectiveness of interventions [11-12]. 71 
Randomization balances, on the average, the distribution of both known and unknown 72 
prognostic factors at baseline in the intervention groups, thereby minimizing selection bias 73 
when assigning patients to treatments.  Although adjusting for baseline covariates used in the 74 
randomization process can improve statistical power, complex adjustment procedures such as 75 
propensity score weighting are not usually required when comparing outcomes. 76 
Patients are selected, treated, followed and assessed according to a common protocol testing a 77 
specific hypothesis. Blinding of participants and physicians to the allocated intervention may be 78 
possible to minimize performance bias, and is especially important when assessing outcomes 79 
[13].  Quality control measures and external review of key parameters maximize study quality. 80 
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Limitations of RCTs 81 
RCTs can be challenging to design (randomization and blinding), conduct (poor recruitment, loss 82 
to follow up), analyze (missing data) and report (patient exclusions). 83 
RCTs require an adequate sample size and follow-up to have sufficient power to detect clinically 84 
relevant differences between interventions [14]. In practice, many clinical trials do not meet 85 
their pre-specified power requirements so a conclusion of ‘no significant difference’ in outcome 86 
should not be interpreted as meaning that two or more treatments are equivalent in effect. 87 
Sample size estimation requires data about expected differences and variability of the primary 88 
outcome. Often these data are unknown or only available from observational studies prone to 89 
bias. 90 
Although analyses using the intention-to-treat principle can provide an unbiased estimate of 91 
the treatment effect, this assumes that there are no differences in follow-up or missing 92 
outcome data that may bias the treatment comparison [15]. In some RCTs, not all participants 93 
receive their randomized intervention; they may, for example, cross-over to the other 94 
randomized treatment, in which case a per-protocol analysis may also provide useful 95 
information. Various analysis strategies exist, depending on whether the objective is to 96 
estimate treatment efficacy (the intervention effect under perfect conditions, in which case 97 
intent to treat can dilute the size of the treatment effect) or effectiveness (the real-world 98 
intervention effect with ‘imperfect’ compliance). 99 
An RCT with double blinding, little missing data and good compliance will have a high internal 100 
validity, but if an RCT recruits only a very select population, the external validity 101 
(generalizability) may be low. This can happen due to overly restrictive inclusion/exclusion 102 
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criteria or including only expert clinicians in select sites [16]. Single-center RCTs typically have 103 
lower external validity compared with multicenter RCTs which allow the comparison of results 104 
between centers. 105 
Finally, robust, adequately powered RCTs with long term follow up are difficult to organize, 106 
expensive and resource-intensive. Thus many RCTs focus on short-term or surrogate outcomes, 107 
the clinical significance of which is often uncertain. Any short-term benefits might not be 108 
maintained over longer time horizons which are more relevant to patients, clinicians and policy 109 
makers [17].  110 
3. Advantages and Limitations of Systematic Reviews and Meta-analyses 111 
Table 2 outlines the advantages and limitations of SR/MAs. 112 
Advantages of SR/MAs 113 
A SR is a literature review focused on a research question that tries to identify, appraise, select 114 
and synthesize all research evidence relevant to that question.  115 
SRs are a priori defined in a PICO (Participant, Intervention, Comparator, Outcome) based 116 
protocol outlining the study inclusion criteria. They are the only transparent and replicable form 117 
of literature review that provide a rigorous and critical qualitative appraisal of the evidence 118 
related to an intervention. SRs explore the findings of individual studies, draw attention to their 119 
differences and identify sources of bias [18]. 120 
A MA is a statistical technique for quantitatively combining the data from two or more separate 121 
RCTs asking the same or a similar question [19]. They should only be done as part of a SR, 122 
otherwise it is a combined analysis, susceptible to study selection bias. Two different types of 123 
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meta-analyses exist: literature-based or aggregate data (AD) MAs and individual patient data 124 
(IPD) MAs [20, 21]. 125 
MAs provide an overall estimate of the size of the treatment effect, giving due weight to the 126 
size of the individual RCTs. They are useful when individual studies are underpowered, yield 127 
inconclusive or conflicting results, or when an overall, more precise estimate of the size of the 128 
treatment effect is required. MAs increase the power to detect moderate but clinically 129 
meaningful differences in treatment outcome and assess if the treatment effect is similar across 130 
different studies or types of patients [22]. They are useful in exploring the effects of an 131 
intervention in subgroups of patients, especially in IPD MAs [20, 21]. 132 
SRs and MAs are vital for guideline developers, healthcare providers, patients, researchers and 133 
policy makers in order to guide clinical practice, research and healthcare policies [23]. 134 
Limitations of SR/MAs 135 
The validity of a MA depends on the quality of the systematic review upon which it is based. SRs 136 
and MAs have a number of potential limitations including poor quality of included studies, 137 
heterogeneity, and publication bias. 138 
The literature summary provided in a SR and the results of a MA are only as reliable as the 139 
quality of the included studies. Although IPD meta-analyses and multicenter RCTs can be 140 
analyzed using the same statistical techniques for clustered data, where the clusters are studies 141 
and centers, respectively, there may be important clinical and methodological heterogeneity 142 
between the studies in a MA since they are not carried out based on a common protocol. The 143 
studies may be heterogeneous regarding patients included, the intervention or the assessment 144 
of treatment outcome. Although heterogeneity in treatment effect can be better investigated 145 
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in IPD MAs, the primary studies should be similar enough to be combined, otherwise genuine 146 
differences in effects may be obscured [24,25]. Since institutions participating in a multicenter 147 
study are supposed to treat, follow up and assess patients according to a common protocol, 148 
there is potentially a greater degree of standardization and higher quality data in multicenter 149 
clinical trials as compared to studies included in meta-analyses. 150 
If bias is present in the individual studies included in a MA, MAs will compound these errors and 151 
produce a biased result. The risk of bias (RoB) on the outcomes in each study should be 152 
systematically assessed and sensitivity analyses performed to examine the effect of RoB on the 153 
conclusions. Observational and non-randomized comparative studies in SRs of interventions 154 
should not be included in MAs because the MA may provide very precise but spurious results 155 
due to confounding and patient selection bias. 156 
Only a non-random proportion of research projects ultimately reach publication in an indexed 157 
journal and become readily identifiable for systematic reviews. Statistically significant, ‘positive’ 158 
results favoring an intervention are more likely to be published, published quicker and 159 
published in higher impact journals, leading to publication bias [26]. When these trials are 160 
pooled together in a MA, this may lead to an exaggeration of the treatment effect. Begg and 161 
Egger have both proposed tests along with funnel graphs and plots to detect publication bias, 162 
however they have limited power in small meta-analyses, for example those including less than 163 
10 studies [27]. In order to minimize publication bias, authors should perform a comprehensive 164 
systematic literature search, looking not only for published trials in various electronic 165 
databases, but also search trial registries for unpublished studies and conference abstracts or 166 
proceedings [18]. 167 
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4. The Results of a Randomized Controlled Trial are in conflict with the Results of a Systematic 168 
Review/Meta-analysis 169 
It is not uncommon for the results of a large RCT to appear to be inconsistent with evidence 170 
from SRs/MAs. The most extreme is when an intervention thought to be beneficial is 171 
demonstrated to be harmful in a large RCT [9,10]. More commonly, an RCT may show a 172 
treatment to be ineffective, or less effective than that found in a previous MA, or perhaps only 173 
effective in a subpopulation of patients. Assuming the conflicting RCT was of high quality, a 174 
number of issues should be explored to try to explain the discrepancies.  175 
Quality of the systematic review 176 
The starting point is the methodological quality of the SR.  AMSTAR and DART checklists [28-30] 177 
allow readers to judge a review’s quality by focusing on the essential components of a well-178 
conducted SR. Items include the comprehensiveness of the search strategy, a description of the 179 
characteristics of included studies and an assessment of their scientific quality.  A poor quality 180 
SR/MA may produce biased results that conflict with a large RCT.      181 
Small study effects and publication bias 182 
Small study effects and publication bias can individually and jointly produce results in a SR/MA 183 
that conflict with a large RCT. Studies have shown that small RCTs can exaggerate intervention 184 
effects due to shortcomings in methodological rigor which may then introduce bias [3]. Small 185 
studies that find statistically significant (but unrealistically large) treatment effects are more 186 
likely to be published than negative studies and then included in an SR and MA, leading to 187 
publication bias. Both of these phenomena can be investigated using funnel plots [31].  188 
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Heterogeneity 189 
Heterogeneity within a SR/MA can arise from many sources, including the population recruited 190 
(age, sex, disease severity, etc.), the intervention(s) and control treatments, and the definition 191 
and timing of outcome measurements.  If studies included in a SR/MA differ substantially from 192 
a subsequent large RCT, then judgement is required on whether similar findings should be 193 
expected. 194 
Another source of heterogeneity is differences in the methodological quality of the included 195 
studies. Deficiencies in the generation and concealment of the allocation sequence, adherence 196 
to treatment, handling of missing data, and outcome assessment can all introduce bias in the 197 
outcomes reported in the included studies [18].  Bias may then be propagated in meta-analyses 198 
through the pooling of biased study effects, thus contributing to different estimates of 199 
effectiveness between a SR/MA and subsequent large RCTs. Nevertheless, since a MA is 200 
generally seen to have a higher LE than a single RCT, the results of a poor quality MA may have 201 
more impact than a well-conducted RCT. 202 
Heterogeneity should be assessed using both clinical knowledge and statistical methods. If 203 
substantial heterogeneity from any source is suspected, random effects models are 204 
recommended, however the pooling of data and estimation of an overall treatment effect may 205 
be inappropriate with any statistical model in the presence of heterogeneity. Meta-regression is 206 
a useful tool to explore the relationship between RCT effect sizes and characteristics on a study 207 
level [32], however IPD are required for assessment on a patient level [21, 33]. Appropriate 208 
statistical modelling may show that after correcting for sources of bias and heterogeneity, 209 
  13 
 
discrepancies between SR/MA and definitive RCTs are reduced. Whatever the approach, 210 
interpretation of results is less straightforward when heterogeneity is present. 211 
In order to provide guidance to clinicians and guideline developers when there is a conflict of 212 
results between a large RCT and a SR/MA, a practical checklist of points to consider is provided 213 
in Table 3. 214 
5. Examples of discrepancies between findings from meta-analyses and large randomized 215 
controlled trials 216 
Medical expulsive therapy 217 
Five SRs and MAs on the management of uncomplicated symptomatic ureteric stones using 218 
medical expulsive therapy (MET) were published in the past 10 years [34-38]. All five suggested 219 
that alpha blockers and nifedipine were more effective in increasing the spontaneous passage 220 
of ureteric stones compared to control (risk ratios ranging from 1.45-1.59). The reviews 221 
identified numerous sources of potential bias which limited the strength of evidence and the 222 
authors concluded an urgent need to conduct a large, robust, multicenter RCT to address these 223 
shortcomings.  Pickard et al [8] published the results of such an RCT in 1167 patients and found 224 
no evidence that either tamsulosin or nifedipine increased the rate of spontaneous stone 225 
passage compared with placebo. Results were consistent across subgroup and sensitivity 226 
analyses.  227 
We compare the Pickard et al RCT [8] to the meta-analysis with the most studies, Seitz et al 228 
[36], to explore and discuss discordant findings. Most RCTs included in Seitz’s meta-analysis 229 
were small and recruited from a single-center; only 6 of 35 (17%) recruited more than 100 230 
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patients. The majority had low internal validity and only one RCT reported allocation 231 
concealment. As small RCTs may report larger effect sizes compared to larger RCTs, a meta-232 
analysis of small RCTs can lead to biased estimates of treatment effects [39]. Seitz also found 233 
evidence of publication bias which can lead to an overestimation of treatment effects and 234 
compromise the validity of the meta-analysis findings [40]. 235 
There was evidence of clinical heterogeneity in Seitz’s review concerning the patient inclusion 236 
criteria, stone characteristics, intervention, treatment in the control group, and outcome 237 
measurement. In the MA, the primary outcome of being stone-free was inconsistently defined, 238 
assessed using different imaging modalities, and measured at a variety of time points. In 239 
Pickard, the primary outcome was need for further intervention within 4 weeks of 240 
randomization, which is compared here to being stone-free. In the control group, 80% of 241 
patients were stone-free in the Pickard RCT whereas in Seitz, the stone-free rates ranged from 242 
4% to 78%, which highlights the potential impact of the heterogeneity in the included studies.  243 
With contrasting primary outcomes and different baseline event rates in the control groups, it 244 
is not surprising that the RCT and the MA reported discordant findings. The choice of primary 245 
outcome is clearly of paramount importance in any trial. Heterogeneity in the conduct, design 246 
and reporting of trials in this MA makes pooled treatment effects difficult, if not impossible, to 247 
interpret.   248 
Partial versus radical nephrectomy 249 
In an EORTC RCT involving 541 patients with a solitary T1-T2 N0 M0 renal tumor < 5 cm, 21 250 
patients progressed, 9 after radical nephrectomy (RN) and 12 after partial nephrectomy (PN). 251 
An intent to treat analysis found an overall survival (OS) advantage in favor of RN (HR = 1.5, p = 252 
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0.03), however only 12 of the 117 deaths were due to kidney cancer, 4 on RN and 8 on PN [10]. 253 
Subsequently, Kim et al published a SR and MA including some 41,000 patients which found 254 
statistically significant improvements in both OS (HR = 0.81, p < 0.001) and disease specific 255 
survival (DSS) (HR = 0.71, p < 0.001), but this time in favor of PN [9]. How can this discordance 256 
be explained? 257 
The Kim meta-analysis has a number of limitations. Firstly, the 38 included trials were mostly 258 
retrospective, single center studies. The only RCT was the EORTC study. No information was 259 
provided about the distribution of follow up or patient characteristics by treatment group (T 260 
category when > T1, tumor size, grade, cell type, or renal function). Consequently, the observed 261 
differences in survival may not be directly due to differences in treatment efficacy. In addition, 262 
it is not clear to which patients the results can be generalized. Lastly, there was significant 263 
heterogeneity in the size of the treatment effect across the studies so the overall estimate of 264 
the HR is not meaningful. Nevertheless, the EORTC RCT also had limitations and should be 265 
interpreted cautiously: 55 patients crossed over to the other randomized treatment, 140 266 
patients were clinically or pathologically ineligible and there were few cancer related events. 267 
The MA found that PN was associated with a decreased risk of severe chronic kidney disease 268 
(CKD), however the EORTC study only found a reduced incidence of at least moderate renal 269 
dysfunction, not of advanced kidney disease or renal failure, and this was not associated with a 270 
corresponding difference in survival [41]. The studies in the MA did not always specify the 271 
status of the contralateral kidney whereas in the EORTC study the contralateral kidney had to 272 
be normal. 273 
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Critical information regarding the biases of the studies included in the SR were not made 274 
explicit since a GRADE approach to assess the quality of evidence was not done [42]. The quality 275 
of the studies in the SR and heterogeneity of results call into question the validity of the 276 
conclusions of the MA which should thus be viewed with skepticism. The same year, another SR 277 
suggested that localised RCCs are best managed by PN where technically feasible. However, the 278 
evidence base had significant limitations due to studies of low methodological quality and high 279 
risks of bias [43]. 280 
Further non-randomized studies have found improved survival with PN [44,45] and a reduction 281 
in the risk of cardiovascular events relative to RN [46], however patients chosen for PN had a 282 
higher baseline likelihood of long-term survival [47,48]. In another study, only stage-II CKD 283 
patients had a decreased risk of developing significant renal impairment on PN [49]. More 284 
recently, a SR and MA of 21 non randomized comparative studies in patients with clinical T1b 285 
and T2 renal tumors found better tumor control and survival with PN as compared to RN [50], 286 
but it is subject to the same biases as the Kim MA. 287 
Taking into account all available efficacy data and a perceived advantage in renal function, the 288 
2016 EAU Guidelines recommend, with several exceptions, that localized renal cancers are 289 
better managed by PN than with RN. 290 
6. Discussion 291 
It is generally accepted that a high quality SR of RCTs and associated MA can provide a higher 292 
level of evidence than a single RCT addressing the same question [2].  It can be problematic, 293 
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however, when the results of the MA are in direct conflict with the RCT, making it difficult for 294 
guideline organizations to interpret the evidence and issue recommendations.   295 
Guideline groups should follow well-defined methodological rules to assess the studies in these 296 
situations.  RCTs should be appraised on their internal and external validity using established 297 
tools [51].  The conflicting SR/MA should be appraised in the same fashion, to determine the 298 
methodological quality of the review, the quality of the included studies, inconsistency within 299 
the studies, unexplained heterogeneity, and likelihood of publication bias using tools such as 300 
AMSTAR [28,29] and DART [30]. In some cases, the discrepancy may be due to errors in the MA 301 
in applying study eligibility criteria or even data extraction [52], hence the need for a SR/MA 302 
protocol and strict quality control.  303 
When MAs include many small underpowered studies, especially combined with likely presence 304 
of publication bias, there is immediate concern for over-inflation of, or completely erroneous, 305 
effect size measurement.  Additionally, when a great degree of heterogeneity exists in the MA 306 
which cannot be easily accounted for, the results may be highly unreliable. In this regard, IPD 307 
MAs provide a better platform for assessing and explaining heterogeneity than aggregate data 308 
MAs.  309 
Two examples were discussed in this manuscript to illustrate the assessment process.  In the 310 
case of MET for ureteric stones, a large, high quality RCT [8] contradicted many well established 311 
MAs which pointed to a benefit with this therapy.  Analysis of a representative MA [36] 312 
revealed the inclusion of many small RCTs, poor internal validity, significant study 313 
heterogeneity and likely publication bias.  When such MA concerns are present, a single high 314 
quality RCT may be considered as having the higher LE.  For guideline organizations, this 315 
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process can be used to justify a change in recommendations based on methodologically sound 316 
principles. 317 
Radical versus partial nephrectomy provides a more complex example.  The MA [9] included 318 
only a single RCT, which was the study in conflict with its own results.  The other included 319 
studies were all retrospective, which in general provide a lower LE.  Risk of bias was poorly 320 
assessed, and significant study heterogeneity was present. It is important to reiterate that 321 
combining observational studies in general, and even comparative non-randomized studies 322 
with RCTs in an intervention MA, may produce unreliable results and is not considered valid.  In 323 
light of all this, the single RCT [10] in this circumstance might provide more guidance than the 324 
MA if it was of significantly high quality.  However, this RCT also had some methodology 325 
concerns, so the comparison is not so simple. 326 
Instead of automatically assigning a higher LE to SR/MAs which conflict with RCTs, these 327 
examples have shown that the quality of the evidence and the RoB of studies included in 328 
SRs/MAs should be assessed to determine which source provides the better evidence.  329 
Although non RCTs can be included in SRs, we have emphasized that only RCTs should be 330 
included in intervention MAs. RCTs are not required for prognostic factor and diagnostic test 331 
accuracy MAs, however the studies included in these MAs should preferably be prospective in 332 
nature and based on a protocol to minimize risk of bias. 333 
Despite the availability of MAs and RCTs, and also in cases where high level evidence does not 334 
exist, we may still not know what the best treatment is. The GRADE system, which takes into 335 
account the quality of evidence (high, moderate, low, very low) for critical outcomes, provides 336 
strengths of recommendations (strong, weak) for or against a treatment to aid clinicians in their 337 
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practice when consensus is not possible [42,53]. A decision curve approach, which takes into 338 
account a patient’s values and preferences, may also be used to help choose between the 339 
different treatment options. 340 
7. Conclusions 341 
New or existing RCT data can lead to conflicts with MA data. In this paper, we present examples 342 
of, and explore reasons for, such conflicts. Guidance is provided to guideline developers on how 343 
to interpret conflicting data in such circumstances to help assess which source is more reliable. 344 
For guideline organizations, both within and outside of urology, having a well-defined and 345 
robust process to deal with such conflicts is essential to improve guideline quality. 346 
 347 
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Table 1: Advantages and Limitations of Randomized Controlled Trials 
 
Advantages Limitations 
Randomization minimizes the influence of both 
known and unknown prognostic variables on 
treatment outcome 
It may be difficult to recruit and 
follow up patients 
RCTs can demonstrate causality Ethical considerations may make 
randomization difficult 
Patients are treated according to a common protocol Required study power might not be 
met 
Quality control of treatment and outcome 
assessment 
Generalizability may be low   
RCTs provide the strongest empirical evidence of 
treatment efficacy 
RCTs are expensive and resource 
intensive 
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Table 2: Advantages and Limitations of Systematic Reviews and Meta-analyses 
 
Advantages Limitations 
 
Focused well defined clinical question 
with a clear objective and explicit, 
predefined study eligibility criteria 
 
Comprehensive literature search 
strategy to guarantee the identification 
of all potentially eligible studies 
 
Critical appraisal of all the included 
studies that is used to guide the 
analysis and conclusions 
 
Increases the power to detect 
differences between interventions 
 
Increases the precision of the estimate 
of the treatment effect 
 
Allows the comparison of treatment 
effects across different studies or 
subgroups of patients, interventions 
and outcomes 
 
Depends on the quality of the included 
studies 
 
Susceptible to the effects of heterogeneity 
of included studies 
 Clinical heterogeneity: 
o Participants (e.g. age, gender, 
disease severity, disease subtype, 
study eligibility criteria) 
o Interventions (e.g. drug doses, 
duration/intensity of treatment, 
delivery, co-interventions, surgeon 
experience) 
o Outcomes (e.g definition of 
outcome, outcomes reported, 
timing and method of 
measurement, follow-up duration, 
cut-off points) 
 Methodological heterogeneity (e.g 
different study designs, reporting bias 
across studies) 
 Statistical heterogeneity 
 
Publication bias 
 
Time and resource consuming 
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Table 3: Checklist of points to consider when the findings from a systematic review and meta-
analysis differ with those from a large randomized controlled trial 
 
Criteria to 
consider 
Questions to ask Rationale 
Selection bias  Were the sequence generation and 
allocation concealment adequate in 
both the studies included in the SR/MA 
and the subsequent trial?  
 
If the sequence generation was 
not truly random or the 
allocation was not effectively 
concealed, this can lead to 
exaggerated estimates in 
individual studies and these 
may be amplified in MAs.  
Confounding 
bias 
Were the groups balanced for known 
prognostic factors at baseline and were 
any imbalances controlled for in the 
analysis? 
 
Imbalances in known and 
unknown prognostic factors are 
possible even in well-designed 
RCTs. Baseline imbalances may 
explain differences in estimates 
of effect if not controlled for in 
the analysis.  
Performance 
and detection 
bias  
Where possible, in all the studies 
included in the SR/MA and for the new 
trial, was blinding of study participants, 
clinicians administering the treatment, 
ancillary care-givers and outcomes 
assessors done?  
When blinding is not possible, could 
knowledge of the treatment received 
affect interpretation of any of the 
outcomes? 
Some objective outcomes are 
unlikely to be affected by 
knowledge of the intervention 
arm, but failure to blind 
(particularly for subjective 
outcomes) may lead to an 
exaggeration of effect sizes in 
individual studies and these 
may be amplified in MAs. 
Attrition bias  Were all dropouts documented and 
unlikely to be related to the treatment 
outcome in the studies included in the 
SR/MA and in the new trial? 
If drop-out rates differ between 
the treatment arms, then the 
reasons may be related to the 
outcome of interest and may 
hide important outcome effects. 
Reporting 
bias  
Were all outcomes that were stated in 
the methods and/or protocol for all the 
studies included in the SR/MA and in 
the new trial reported in the trial 
report? 
Were all the outcomes measured 
appropriately (as defined in the 
protocol) or were deviations 
Selective reporting of outcomes, 
or selective methods of 
reporting, may lead to 
exaggerated estimates of effect 
Table 3
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reasonably explained? 
Publication 
bias  
Were funnel plots used to investigate 
publication bias in the SR/MA? Is the 
funnel plot symmetrical or is there 
reason to believe there is a systematic 
difference between published and 
unpublished studies? 
Note: this is difficult to assess when 
there are less than 10 RCTs 
contributing to a MA.  
Asymmetric funnel plots raise 
suspicion that there are 
systematic differences between 
published and unpublished 
studies and that some positive 
or negative trials may be 
unpublished. The may lead to 
exaggerated effect sizes in a MA 
Consistency 
and 
heterogeneity 
of outcome 
Did the studies included in the SR/MA 
have overlapping 95% CIs for the 
outcome?  
Was variation more than would be 
expected by chance alone? 
Was the I² statistic <40% ? 
(Cochrane/GRADE rule of thumb…) 
Were subgroups used to explain any 
observed heterogeneity? 
Were event rates in the control group 
similar in the different studies? 
Note: Subgroups of the population, the 
intervention/control types, or the 
outcome measurement may explain 
heterogeneity.  
If the outcomes can be shown 
to be more effective in certain 
subgroups, or with variations of 
an intervention (e.g. a higher 
dose), then this explained 
heterogeneity may indicate a 
key difference which may justify 
the results in the new trial.  
Where unexplained 
heterogeneity exists, then the 
estimate of effect is likely to be 
uncertain, even if precise.  
Directness  Do the studies included in the SR/MA 
and does the new trial both directly 
assess the research question about the 
population, interventions and 
outcomes?  
Indirect populations, 
interventions, surrogate 
outcome measures or indirect 
comparisons may conceal or 
exaggerate important 
differences within and between 
studies and may impact upon 
the estimate of effect.  
Precision  Were the sample sizes of the studies 
included in the SR/MA and the new 
trial powered to address the outcomes 
of interest?  
Does the 95% CI in the MA include 
clinically judged appreciable benefit 
and harm? 
If any of the SR/MA included 
trials, or the new trial were not 
powered to detect a clinically 
meaningful difference in the 
effect estimate, this may reduce 
our confidence in the estimate 
of effect.  
If the lower and upper 95% CI 
thresholds indicate that at one 
end the intervention may be 
beneficial, but at the other, it 
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may be harmful, this will likely 
reduce our confidence in the 
estimate of effect.  
Sensitivity 
analyses  
When some studies included in a 
SR/MA are judged to be at high risk of 
bias, and others at low risk of bias, or 
extreme variations in the included 
studies’ populations or interventions 
are apparent: did the authors conduct 
a sensitivity analysis to ascertain the 
estimates of effect on only those 
studies judged to be at low risk of bias?  
Sensitivity analyses are different 
from subgroup analyses. Some 
studies are actively omitted as 
we are only interested in the 
results when the biased or 
‘different’ studies are omitted.  
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